Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.35 |
| ▸ | RARG | P13631 | 2/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477078 | 0.80 | CYP26A1 (0.33) | RARBRARGCYP26A1CYP3A4RARA | |
| SCHEMBL3300659 | 0.77 | RARB (0.55) | RARBRARGCYP26A1CYP3A4RARA | |
| SCHEMBL9328615 | 0.71 | RARA (0.35) | RARBRARGCYP26A1CYP3A4RARA | |
| SCHEMBL4509176 | 0.70 | GABRA5 (0.34) | RARBRARGCYP26A1CYP3A4RARA | |
| SCHEMBL8866654 | 0.69 | RARB (0.33) | RARBRARG | |
| SCHEMBL6664854 | 0.68 | RARB (0.61) | RARBRARGCYP26A1CYP3A4RARA | |
| SCHEMBL8631884 | 0.67 | RARB (0.63) | RARBRARGCYP26A1CYP3A4RARA | |
| SCHEMBL8629043 | 0.67 | RARB (0.50) | RARBRARGRARA | |
| SCHEMBL9028813 | 0.66 | RARB (0.38) | RARBRARGCYP26A1CYP3A4RARA | |
| SCHEMBL4849205 | 0.66 | AKR1B1 (0.33) | RARBRARGCYP26A1CYP3A4RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921777-B2 | Heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-26 | — | — | US | disclosed |
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-01-16 | — | — | US | disclosed |
| US-6444709-B1 | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | TYR, CYP1B1, MITF | RARB 1728/4885RARG 1282/4885CYP26A1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.